166 related articles for article (PubMed ID: 32943490)
1. Expression of the immunoproteasome subunit β5i in non-small cell lung carcinomas.
Kiuchi T; Tomaru U; Ishizu A; Imagawa M; Iwasaki S; Suzuki A; Otsuka N; Ohhara Y; Kinoshita I; Matsuno Y; Dosaka-Akita H; Kasahara M
J Clin Pathol; 2021 May; 74(5):300-306. PubMed ID: 32943490
[TBL] [Abstract][Full Text] [Related]
2. Evaluating the immunoproteasome as a potential therapeutic target in cisplatin-resistant small cell and non-small cell lung cancer.
Shoji T; Kikuchi E; Kikuchi J; Takashima Y; Furuta M; Takahashi H; Tsuji K; Maeda M; Kinoshita I; Dosaka-Akita H; Sakakibara-Konishi J; Konno S
Cancer Chemother Pharmacol; 2020 May; 85(5):843-853. PubMed ID: 32232513
[TBL] [Abstract][Full Text] [Related]
3. The immunoproteasomes are key to regulate myokines and MHC class I expression in idiopathic inflammatory myopathies.
Bhattarai S; Ghannam K; Krause S; Benveniste O; Marg A; de Bruin G; Xin BT; Overkleeft HS; Spuler S; Stenzel W; Feist E
J Autoimmun; 2016 Dec; 75():118-129. PubMed ID: 27522114
[TBL] [Abstract][Full Text] [Related]
4. An inhibitor of proteasome β2 sites sensitizes myeloma cells to immunoproteasome inhibitors.
Downey-Kopyscinski S; Daily EW; Gautier M; Bhatt A; Florea BI; Mitsiades CS; Richardson PG; Driessen C; Overkleeft HS; Kisselev AF
Blood Adv; 2018 Oct; 2(19):2443-2451. PubMed ID: 30266819
[TBL] [Abstract][Full Text] [Related]
5. Expression of N-acetylglucosaminyltransferase v is associated with prognosis and histology in non-small cell lung cancers.
Dosaka-Akita H; Miyoshi E; Suzuki O; Itoh T; Katoh H; Taniguchi N
Clin Cancer Res; 2004 Mar; 10(5):1773-9. PubMed ID: 15014031
[TBL] [Abstract][Full Text] [Related]
6. A Cell-Based Platform for the Investigation of Immunoproteasome Subunit β5i Expression and Biology of β5i-Containing Proteasomes.
Burov A; Funikov S; Vagapova E; Dalina A; Rezvykh A; Shyrokova E; Lebedev T; Grigorieva E; Popenko V; Leonova O; Spasskaya D; Spirin P; Prassolov V; Karpov V; Morozov A
Cells; 2021 Nov; 10(11):. PubMed ID: 34831272
[TBL] [Abstract][Full Text] [Related]
7. Identification of N, C-capped di- and tripeptides as selective immunoproteasome inhibitors.
Nan G; Huang L; Li Y; Yang Y; Yang Y; Li K; Lai F; Chen X; Xiao Z
Eur J Med Chem; 2022 Apr; 234():114252. PubMed ID: 35286927
[TBL] [Abstract][Full Text] [Related]
8. Inhibiting the immunoproteasome's β5i catalytic activity affects human peripheral blood-derived immune cell viability.
Pletinckx K; Vaßen S; Schlusche I; Nordhoff S; Bahrenberg G; Dunkern TR
Pharmacol Res Perspect; 2019 Aug; 7(4):e00482. PubMed ID: 31236277
[TBL] [Abstract][Full Text] [Related]
9. Methionine Aminopeptidase 2 as a Potential Therapeutic Target for Human Non-Small-Cell Lung Cancers.
Shimizu H; Yamagishi S; Chiba H; Ghazizadeh M
Adv Clin Exp Med; 2016; 25(1):117-28. PubMed ID: 26935506
[TBL] [Abstract][Full Text] [Related]
10. Proteasome Levels and Activity in Pregnancies Complicated by Severe Preeclampsia and Hemolysis, Elevated Liver Enzymes, and Thrombocytopenia (HELLP) Syndrome.
Berryman K; Buhimschi CS; Zhao G; Axe M; Locke M; Buhimschi IA
Hypertension; 2019 Jun; 73(6):1308-1318. PubMed ID: 31067191
[TBL] [Abstract][Full Text] [Related]
11. Virtual Screening Strategy and In Vitro Tests to Identify New Inhibitors of the Immunoproteasome.
Culletta G; Tutone M; Ettari R; Perricone U; Di Chio C; Almerico AM; Zappalà M
Int J Mol Sci; 2023 Jun; 24(13):. PubMed ID: 37445688
[TBL] [Abstract][Full Text] [Related]
12. Development of peptide epoxyketones as selective immunoproteasome inhibitors.
Li X; Hong D; Zhang M; Xu L; Zhou Y; Li J; Liu T
Eur J Med Chem; 2021 Oct; 221():113556. PubMed ID: 34087498
[TBL] [Abstract][Full Text] [Related]
13. Elevated expression of BIRC6 protein in non-small-cell lung cancers is associated with cancer recurrence and chemoresistance.
Dong X; Lin D; Low C; Vucic EA; English JC; Yee J; Murray N; Lam WL; Ling V; Lam S; Gout PW; Wang Y
J Thorac Oncol; 2013 Feb; 8(2):161-70. PubMed ID: 23287853
[TBL] [Abstract][Full Text] [Related]
14. Immunoproteasome deficiency is a feature of non-small cell lung cancer with a mesenchymal phenotype and is associated with a poor outcome.
Tripathi SC; Peters HL; Taguchi A; Katayama H; Wang H; Momin A; Jolly MK; Celiktas M; Rodriguez-Canales J; Liu H; Behrens C; Wistuba II; Ben-Jacob E; Levine H; Molldrem JJ; Hanash SM; Ostrin EJ
Proc Natl Acad Sci U S A; 2016 Mar; 113(11):E1555-64. PubMed ID: 26929325
[TBL] [Abstract][Full Text] [Related]
15. Expression of fucosyltransferase 8 is associated with an unfavorable clinical outcome in non-small cell lung cancers.
Honma R; Kinoshita I; Miyoshi E; Tomaru U; Matsuno Y; Shimizu Y; Takeuchi S; Kobayashi Y; Kaga K; Taniguchi N; Dosaka-Akita H
Oncology; 2015; 88(5):298-308. PubMed ID: 25572677
[TBL] [Abstract][Full Text] [Related]
16. The immunoproteasome β5i subunit is a key contributor to ictogenesis in a rat model of chronic epilepsy.
Mishto M; Raza ML; de Biase D; Ravizza T; Vasuri F; Martucci M; Keller C; Bellavista E; Buchholz TJ; Kloetzel PM; Pession A; Vezzani A; Heinemann U
Brain Behav Immun; 2015 Oct; 49():188-96. PubMed ID: 26044087
[TBL] [Abstract][Full Text] [Related]
17. Immunoproteasome-selective and non-selective inhibitors: A promising approach for the treatment of multiple myeloma.
Ettari R; Zappalà M; Grasso S; Musolino C; Innao V; Allegra A
Pharmacol Ther; 2018 Feb; 182():176-192. PubMed ID: 28911826
[TBL] [Abstract][Full Text] [Related]
18. Two abundant proteasome subtypes that uniquely process some antigens presented by HLA class I molecules.
Guillaume B; Chapiro J; Stroobant V; Colau D; Van Holle B; Parvizi G; Bousquet-Dubouch MP; Théate I; Parmentier N; Van den Eynde BJ
Proc Natl Acad Sci U S A; 2010 Oct; 107(43):18599-604. PubMed ID: 20937868
[TBL] [Abstract][Full Text] [Related]
19. Immunoproteasome-specific inhibitors and their application.
Basler M; Groettrup M
Methods Mol Biol; 2012; 832():391-401. PubMed ID: 22350900
[TBL] [Abstract][Full Text] [Related]
20. Nonpeptidic Selective Inhibitors of the Chymotrypsin-Like (β5 i) Subunit of the Immunoproteasome.
Sosič I; Gobec M; Brus B; Knez D; Živec M; Konc J; Lešnik S; Ogrizek M; Obreza A; Žigon D; Janežič D; Mlinarič-Raščan I; Gobec S
Angew Chem Int Ed Engl; 2016 May; 55(19):5745-8. PubMed ID: 27037901
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
